CC chemokine receptor 5Δ32 polymorphism - A risk factor for ischemic-type biliary lesions following orthotopic liver transplantation

Liver Transplantation

Volumn 10, Issue 3, 2004, Pages 434-439

  Moench, Christian ^a   Uhrig, Anja ^b   Lohse, Ansgar W ^a   Otto, Gerd ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BETA CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CREATININE; CYCLOSPORIN A; GAMMA GLUTAMYLTRANSFERASE; GANCICLOVIR; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIARY TRACT DISEASE; BLOOD SAMPLING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENETIC POLYMORPHISM; GRAFT SURVIVAL; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; RISK FACTOR; SCREENING TEST; WILD TYPE;

ADULT; BILE DUCTS, INTRAHEPATIC; BILIARY TRACT DISEASES; HUMANS; ISCHEMIA; LIVER TRANSPLANTATION; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, CCR5; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 1642303184     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20095     Document Type: Article

References (40)

1. Kadmon M, Bleyl J, Küppers B, Otto G, Herfarth C. Biliary complications after prolonged UW-preservation of liver allografts. Transplant Proc 1993;25:1288.
2. McMaster P, Herbertson B, Cusick C, Calne R, Williams R. Biliary sludging following liver transplantation in man. Transplantation 1978;25:56-62.
3. Guichelaar M, Benson J, Malinchoc M, Krom R, Wiesner R, Charlton M. Risk factors for and clinical course of non-anastomotic biliary strictures after liver transplantation. Am J Transplant 2003;3:885-890.
4. Colonna J, Shaked A, Gomes A, Colquhoun SD, Jurim O, McDiarmid SV, et al. Biliary strictures complicating liver transplantation. Incidence, pathogenesis, management, and outcome. Ann Surg 1992;216:344-350.
5. Otto G, Roeren T, Golling M, Datsis K, Hofmann WJ, Herfarth C, Theilmann L. Ischemic type lesions of the bile ducts after liver transplantation: 2 years results. Zentralbl Chir 1995;120:450-454.
6. Sanchez-Urdazpal L, Gores G, Ward E, Maus TP, Wahlstrom HE, Moore SB, et al. Ischemic-type biliary complications after orthotopic liver transplantation. Hepatology 1992;16:49-53.
7. Sanchez-Urdazpal L, Gores G, Ward E, Maus TP, Buckel EG, Steers JL, et al. Diagnostic features and clinical outcome of ischemic-type-biliary complications after orthotopic liver transplantation. Hepatology 1993;17:605-609.
8. Hintze R, Adler A, Veltzke W, Abou-Rebyeh H, Felix R, Neuhaus P. Endoscopic management of biliary complications after orthotopic liver transplantation. Hepatogastroenterology 1997; 44:158-262.
9. Hintze R, Abou-Rebyeh H, Adler A, et al. Endoscopic therapy of ischemia-type biliary lesions in patients following orthotopic liver transplantation. Z Gastroentrol 1999;37:13-20.
10. Schlitt H, Meier P, Nashan B, Oldhafer KJ, Boeker K, Flemming P, et al. Reconstructive surgery for ischemic type lesions at the bile duct bifurcation after liver transplantation. Ann Surg 1999; 229:137-145.
11. Theilmann L, Kuppers B, Kadmon M, Roeren T, Notheisen H, Stiehl A, Otto G. Biliary tract strictures after orthotopic liver transplantation: Diagnosis and management. Endoscopy 1994; 26:517-522.
12. Li S, Stratta R, Langnas A, Wood R, Marujo W, Shaw BJ. Diffuse biliary tract injury after orthotopic liver transplantation. Am J Surg 1992;164:536-540.
13. Iwatsuki S, Shaw BJ, Starzl T. Biliary tract complications in liver transplantation under cyclosporine-steroid therapy. Transplant Proc 1983;15:1288.
14. Langrehr J, Schneller A, Neuhaus R, Vogl T, Hintze R, Neuhaus P. Etiologic factors and incidence of ischemic type biliary lesions (ITBL) after liver transplantation. Langenbecks Arch Chir Suppl Kongressbd 1998;115:1560-1562.
15. Moench C, Moench K, Lohse A, Thies J, Otto G. Prevention of ischemic-type biliary lesions by arterial back-table pressure perfusion. Liver Transpl 2003;9:285-289.
16. Golling M, Zipperle S, Weimer R, Otto G, Herfarth C, Opelz G, Klar E. Chronic liver immunologic factors in ischemic type biliary lesions (ITBL)-reduced TH1 and increased Th2 response. Langenbecks Arch Chir Suppl Kongressbd 1998;115:1557-1559.
17. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. New Eng J Med 1998;338:436-445.
18. Hancock WW, Gao W, Faia KL, Csizmadia V. Chemokines and their receptors in allograft rejection. Curr Opin Immunol 2000; 12:511-516.
19. Moench C, Uhrig A, Wunsch A, Thies J, G O. Chemokines: Reliable markers for diagnosis of rejection and inflammation following orthotopic liver transplantation. Transplant Proc 2001;33:3293-3294.
20. Fischereder M, Luckow B, Hocher B, Wuthrich RP, Rothenpieler U, Schneeberger H, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001;2:1725-1726.
21. Schroeppel B, Fischereder M, Ashkar R, Lin M, Kramer BK, Mardera B, et al. The impact of polymorphism in chemokine and chemokine receptors on outcomes in liver transplantation. Am J Transplant 2002;2:640-645.
22. Starzl TE, Marchioro TL, Von Kaulla KN, Hermann G, Britiain RS, Waddell WR. Homotransplantation of the liver in humans. Surg, Gynecol Obstet 1963;117:659-664.
23. Starzl T, Putnam C, Hansbrough J, Porter K, Reid H. Biliary complications after liver transplantation: With special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery 1977;81:212-221.
24. Waldram R, Williams R, Calne R. Bile composition and bile cast formation after transplantation of the liver in man. Transplantation 1975;19:382-387.
25. Sebagh M, Blakolmer K, Falissard B, Roche B, Emile JF, Bismuth H, et al. Accuracy of bile duct changes for the diagnosis of chronic liver allograft rejection. Hepatology 2002;35:117-125.
26. Sanchez-Urdazpal L, Sterioff S, Janes C, Schwermann L, Rosen C, Krom R. Increased bile duct complications in ABO incompatible liver transplant recipients. Transplant Proc 1991;23:1440-1441.
27. Tzakis;A, Gordon R, Shaw Bj, Iwatsuki S, Starzl T. Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplant 1985;40:667.
28. Zajko A, Campbell W, Logsdon G, Bron KM, Tzakis A, Esquivel CO, Starzl TE. Cholangiographic findings in hepatic artery occlusion after liver transplantation. AJR 1987;149:485-489.
29. Lerut J, Demetris A, Stieber A, Marsh JW, Gordon RD, Esquivel CO, et al. Intrahepatic bile duct strictures after human orthotopic liver transplantation. Recurrence of primary sclerosing cholangitis or unusual presentation of allograft rejection? Transplant Int 1988;1:127-130.
30. Todo S, Nery J, Yanaga K, Podesta L, Gordon R, Starzl T. Extended preservation of human liver grafts with UW solution. JAMA 1989;261:711-744.
31. Abt P, Crawford M, Desai N, Markmann J, Olthoff K, Shaked A. Liver transplantation from controlled non-heart-beating donors: An increase of biliary complications. Transplantation 2003;75:1659-1663.
32. Horiguchi K, Kitagawa-Sakakida S, Sawa Y, Li ZZ, Fukushima N, Shirakura R, Matsuda H. Selective chemokine and receptor gene expressions in allografts that develop transplant vasculopathy. J Heart Lung Transplant 2002;21:1090-1100.
33. Abdi R, Tran T, Sahagun-Ruiz A, Murphy PM, Brenner BM, Milford EL, McDermott DH. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol. 2002;13:754-758.
34. Gao W, Faia K, Csizmadia V, Smiley ST, Soler D, King JA, et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001;72:1199-1205.
35. Morland CM, Fear J, McNab G, Joplin R, Adams DH. Promotion of leukocyte transendothelial cell migration by chemokines derived human biliary epithelial cells in vitro. Proc Assoc Am Physicians 1997;109:372-382.
36. Curtin J, Cantino D, Biasi F, Chiarpotto E, Salizzoni M, Andorno E, et al. Reperfusion damage to the bile canaliculi in transplanted human liver. Hepatology 1996;24:1053-1057.
37. Worster A, Ghent C. Cholangiographic appearances of ductular rejection of ABO-incompatible liver transplants. J Clin Gastroenterol 1992;15:222-224.
38. Sanchez-Urdazpal L, Sterioff S, Janes C, Schwerman L, Rosen C, Krom RA. Increased bile duct complications in ABO incompatible liver transplant recipients. Transplant Proc 1991;23:1440-1441.
39. Kozaki K, Kasahara M, Oike F, Ogawa K, Fujimoto Y, Ogura Y, et al. Apheresis therapy for living-donor liver transplantation: Experience for apheresis use for living-liver transplantation at Kyoto University. Ther Apher 2002;6:478-483.
40. Erhard J, Lange I, Scherer R, Kox WJ, Bretschneider HJ, Gebhard MM, Eigler FW. Comparison of histidine-tryptophan-ketoglutarate (HTK) solution versus University of Wisconsin (UW) solution for organ preservation in human liver transplantation. A prospective, randomized study. Transpl Int 1994;7:177-181.